Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
0.726
-0.013 (-1.79%)
At close: Feb 21, 2025, 4:00 PM
0.710
-0.016 (-2.15%)
After-hours: Feb 21, 2025, 5:13 PM EST
Oncolytics Biotech Employees
Oncolytics Biotech had 29 employees as of December 31, 2022. The number of employees increased by 3 or 11.54% compared to the previous year.
Employees
29
Change (1Y)
3
Growth (1Y)
11.54%
Revenue / Employee
n/a
Profits / Employee
-$705,557
Market Cap
55.88M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 29 | 3 | 11.54% |
Dec 31, 2021 | 26 | 1 | 4.00% |
Dec 31, 2020 | 25 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
ONCY News
- 4 days ago - Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 - PRNewsWire
- 5 days ago - Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer - PRNewsWire
- 8 days ago - Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency - PRNewsWire
- 15 days ago - Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence - PRNewsWire
- 4 weeks ago - Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium - PRNewsWire
- 5 weeks ago - Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data - PRNewsWire
- 2 months ago - Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data - PRNewsWire
- 2 months ago - Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium - PRNewsWire